| Publisher’s Note: Join us September 11-14 in Philadelphia for Digital Pharma East! We’re excited to announce our opening keynote, none other than Dustin Garis, world-renowned brand innovator, customer experience pioneer and Chief Troublemaker. Register today for the ultimate marketing event in the life sciences industry. |
Today's Big NewsAug 2, 2023 |
|
October 5-6, 2023 San Diego, CA Join us at the Fierce Medical Affairs Strategic Summit West and hear industry-leading speakers from Amgen, Abbott, Bayer, Gilead, Janssen, Otsuka, Daiichi Sankyo, and many more. Register now with early bird rates and save $200.
|
|
| By Annalee Armstrong Early-stage investments in biopharma are up this year, but valuations have come way down. investors are looking for proven leadership teams and an exit strategy that does not involve waiting for the IPO window to magically open up, according to a new H1 analysis by Silicon Valley Bank. |
|
|
|
By Nick Paul Taylor CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder cancer clinical trial has persuaded investors to dig out their checkbooks and pump $105 million into the business. |
By Annalee Armstrong We take protecting anonymous sources around here seriously. So when we do use one, you know the subject is important. Fierce Biotech tracked down the Twitter/X biotech meme over lord/lady Goose Data. |
By Nick Paul Taylor Surface Oncology has shown investors the ghost of biotech yet to come. Needing shareholder support for its planned merger with Coherus BioSciences, the biotech has told investors that outlays triggered by the deal have shrunk its cash runway and will leave it needing funding fast if the deal collapses. |
By Helen Floersh Researchers from City of Hope have pinned down the mechanism behind an oral chemotherapy that is already being tested in humans, adding weight to the preclinical package of data underpinning the drug's potential in a range of solid tumors. |
By Annalee Armstrong Sanofi will be the inaugural partner for the Scleroderma Research Foundation’s new clinical trial initiative to advance treatments for the rare autoimmune disorder of the skin and organs. |
By Conor Hale In February, Abbott and the FDA notified clinicians that studies pointed toward higher rates of aortic valve implant failures in the first five years. |
By Kevin Dunleavy Merck’s $10.8 billion acquisition of Prometheus Biosciences earlier this year gave the New Jersey company increased diversity in its portfolio, much needed considering its overwhelming dependence on cancer juggernaut Keytruda. But buying out the San Diego immunology specialist has not satisfied Merck’s appetite for M&A, executives said. |
By Frank Diamond The world hasn't been this close to nuclear war since the Cold War, say experts. Editors of prestigious medical journals sound a call to disarm. |
By Fraiser Kansteiner Paxlovid generated just $143 million in worldwide sales for the second quarter, while mRNA vaccine Comirnaty brought home $1.4 billion. Against that backdrop, Pfizer reported total second quarter revenues of $12.7 billion, down a whopping 53% operationally from the same period last year. |
By Anastassia Gliadkovskaya Those affected will reportedly receive severance pay, benefits and help with landing a new job elsewhere. CVS Health does not expect customer-facing roles in stores, pharmacies and clinics to be affected in the layoff plan. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we take a critical look at value-based care. Also under discussion is the top nonprofit health systems of 2022. |
|
|---|
|
|
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLeading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
